Connect with us

Health

New review sheds light on risks of cannabis use in pregnancy

Published

on

A new study offers more insights into the complex relationship between prenatal cannabis exposure and neuropsychiatric outcomes in children. 

As the global trend toward cannabis legalisation continues, the prevalence of cannabis use among pregnant women is on the rise, raising concerns about its impact on foetal development.

A new study led by researchers in the Faculty of Medicine at Hebrew University in collaboration with the Hadassah Medical Center, sheds light on the potential long-term neuropsychiatric risks associated with prenatal cannabis exposure.

The comprehensive systematic review and meta-analysis involving over 500,000 participants from observational studies, aimed to assess the potential risks posed by prenatal exposure to THC, the primary psychoactive compound in cannabis. THC is known to cross the placenta, potentially affecting the developing foetal brain.

What the study found

The findings indicate no significant association between prenatal cannabis exposure and an increased risk of autism spectrum disorder (ASD), psychotic symptoms, anxiety, or depression in offspring. 

However, the study did identify a slight increase in the risk of attention-deficit/hyperactivity disorder (ADHD) and a heightened vulnerability to cannabis consumption in children exposed to cannabis in utero.

“These findings suggest that while prenatal cannabis exposure does not appear to significantly increase the risk for many neuropsychiatric disorders, there is still a mild increase in the risk for ADHD and a greater likelihood of cannabis use in the offspring,” said Professor Ilan Matok from the Department of Clinical Pharmacy at the School of Pharmacy at Hebrew University, in a news release.

“This calls for cautious interpretation, as it does not confirm the safety of cannabis consumption during pregnancy.”

Why women consume during pregnancy

Despite many women using cannabis medicinally, the majority of existing studies have only looked at the effects of recreational cannabis, due to the challenges of prescribing in this population. 

Research from 2021 found that many women who consumed cannabis during pregnancy did so to manage pregnancy-related symptoms and pre-existing conditions,​​ including pain management, anxiety, depression, muscle spasms, nausea or appetite, and sleep.

READ MORE: Medical cannabis and pregnancy – what you need to know

Continued research essential for future public health recommendations 

This study marks a significant step forward in understanding the complex relationship between prenatal cannabis exposure and neuropsychiatric outcomes in children. 

However, it also emphasises the importance of continued research in this area, especially given that most of the studies on the subject were conducted between the 1980s and early 2000s, when cannabis was characterised by considerably lower levels of THC content than currently used compounds. 

The researchers warn that findings presented in the current study may potentially underestimate the impact of contemporary prenatal cannabis exposure on the long-term neuropsychiatric outcomes.

As the legal landscape surrounding cannabis continues to evolve, more studies will be essential in guiding public health recommendations.

Professor Matok added: “While our study provides important insights, it is crucial to recognize that these results are not definitive. Pregnant women should be aware of the potential risks, and healthcare providers should continue to advise caution when it comes to cannabis use during pregnancy.”

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.